Health Care · Pharmaceutical Preparations

MPLT MapLight Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 177006991 filings
Russell 2000

MPLT at a glance

MapLight Therapeutics, Inc. (MPLT, SEC CIK 1770069) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as October 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 19 institutional investment managers tracked by SignalX reported holding MapLight Therapeutics, Inc. (MPLT) shares worth $88.1 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Kreitzer Anatol on October 15, 2026 of 12,248 shares at $7.84 per share.
  • In the last 90 days, MPLT insiders reported 0 open-market purchases ($0) and 7 open-market sales ($1.3M) on Form 4, a net sale of $1.3M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 7 sells
Net −$1.3M
13F holders
19 funds
$88.1M · −2 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 7.01 · Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly triggered supply-chain risk: BIOSECURE Act enacted December 18, 2025 may affect a CDMO and restrict certain Chinese biotechnology suppliers
  • Most materially updated regulatory risk: OBBBA signed July 4, 2025 may reduce ACA coverage and Medicaid enrollment
  • Clinical risk: IRIS Phase 2 failed its primary endpoint in June 2026
  • Operational risk: ML-007C-MA relies on limited single-source manufacturing suppliers
  • Financial risk: $463.4 million cash, equivalents and investments expected to fund operations through 2028

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, with no product sales
  • Operating margin not applicable, operating loss $55.3M vs $31.5M YoY
  • R&D expenses $44.2M vs $27.1M, driven by clinical trials and employee costs
  • Cash, equivalents and investments $463.4M; operating cash used $131.7M
  • Outlook: cash expected to fund operations through 2028, further funding required thereafter

AI summary of the MPLT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Updated corporate presentation signals refreshed investor messaging as of November 16, 2026
  • Presentation available on MapLight Therapeutics’ website and furnished as Exhibit 99.2

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Investor-relevant figures and management commentary contained in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q3 net loss $51.6M, versus $29.4M, reflecting sharply higher clinical development spending
  • Cash, equivalents and investments $463.4M, expected to fund operations through 2028 and key clinical readouts

Item EX-99.2: Item EX-99.2

  • Corporate presentation dated November 16, 2026 highlights ML-007C-MA as the lead schizophrenia and Alzheimer’s disease psychosis asset
  • ZEPHYR-1 met its primary endpoint, with PANSS effect size 0.37 and cognitive composite effect size 0.51
Filed Nov 16, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • ATM facility authorizes up to $100 million in common-stock sales, providing MapLight flexible funding access
  • Potential equity issuance creates shareholder dilution risk, depending on shares sold
Filed Aug 13, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • $150.0 million gross private placement, strengthening funding for MapLight’s operations and development programs
  • 9,197,887 common shares plus pre-funded warrants for 3,983,168 shares at $11.38 per share, creating substantial dilution

Item 3.02: Unregistered Sales of Equity Securities

  • Unregistered securities issued in a private placement under Securities Act Section 4(a)(2)
  • Securities subject to resale restrictions absent registration or another exemption

Item EX-99.3: Item EX-99.3

  • August 13 presentation highlights ML-007C-MA as MapLight’s lead asset, with schizophrenia Phase 3 planning and Alzheimer’s disease psychosis results expected in 2H 2027
  • ZEPHYR Phase 2 met its primary endpoint, PANSS effect size 0.37 mITT and 0.50 among completers, supporting planned registrational development

Item 7.01: Regulation FD Disclosure

  • Updated corporate presentation signals refreshed investor messaging and potentially new clinical, pipeline, or corporate milestones
  • Presentation available on MapLight Therapeutics’ website and furnished as Exhibit 99.3

Item EX-99.2: Item EX-99.2

  • $150M PIPE financing, strengthening liquidity for late-stage clinical development
  • 9,197,887 shares sold at $11.38, plus pre-funded warrants for 3,983,168 shares

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results covered quarter ended June 30, 2026, with full results in Exhibit 99.1
  • Cash, cash equivalents and investments totaled $351.3 million at June 30, 2026

Item EX-99.1: Item EX-99.1

  • Positive Phase 2 ZEPHYR results support planned registrational Phase 3 ZEPHYR-2 in schizophrenia, with topline results expected in 2028
  • ML-007C-MA advanced as the lead asset across schizophrenia and ADP; VISTA enrollment ongoing with results expected in the second half of 2027

AI summaries of MPLT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for MPLT

Don't miss the next MPLT filing

  • Alerts as it files. A push when MPLT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut MPLT, by share count.
  • Ask anything. An AI agent that reads every MPLT filing and answers with sources.

MPLT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Kreitzer AnatolSellOct 15, 2026$7.84
Kroeger Christopher A.SellOct 15, 2026$8.08
GILLIS JONATHANSellOct 15, 2026$8.08
Lillie James WoodruffSellOct 15, 2026$8.08
Hanson KristopherSellOct 15, 2026$8.08
Foff Erin PennockSellOct 15, 2026$8.08
Hanson KristopherSellSep 16, 2026$11.67
GILLIS JONATHANAAug 17, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income--$82.9M-$169.1M
Net Income--$77.6M-$161.2M
Balance Sheet
Total Assets-$136.9M$479.5M
Equity-$117.6M-$193.6M$458.4M
ROE-40.1%-35.2%
Per Share
EPS-$-105.38$-18.56
Cash Flow
Operating CF--$78.8M-$138.1M
CapEx-$770K$473K

Source: XBRL data in MapLight Therapeutics, Inc. (MPLT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate MPLT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
MPLT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202619$88.1M
Q2 202621$265.4M
Q1 202616$103.7M
Q4 202516$81.8M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 72 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

MPLT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 16, 2026Analysis
8-KNov 16, 2026Analysis-
8-KNov 16, 2026Analysis-
4Oct 16, 2026--
4Oct 16, 2026--
4Oct 16, 2026--
4Oct 16, 2026--
4Oct 16, 2026--
4Oct 16, 2026--
4Sep 18, 2026--
SC 13GAug 20, 2026-
4Aug 19, 2026--
4Aug 19, 2026--
4Aug 19, 2026--
4Aug 19, 2026--
4Aug 19, 2026--
4Aug 19, 2026--
4Aug 18, 2026--
8-KAug 13, 2026Analysis-
10-QAug 13, 2026Analysis
4Aug 4, 2026--
4Jul 30, 2026--
4Jul 28, 2026--
8-KJul 27, 2026Analysis-
4Jul 20, 2026--

Related Health Care companies

All Health Care →

MPLT SEC filings: frequently asked questions

Are MPLT insiders buying or selling?

In the last 90 days, MapLight Therapeutics, Inc. (MPLT) officers, directors and 10% owners reported no open-market purchases and 7 open-market sales worth $1.3 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold MPLT stock?

As of September 30, 2026, the largest MapLight Therapeutics, Inc. (MPLT) holders among the 13F filers tracked by SignalX were Goldman Sachs Group ($36.7 million), BlackRock ($17.5 million), T. Rowe Price Group ($11.5 million), Two Sigma Investments ($5.3 million), Millennium Management ($4.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did MPLT report in its latest 8-K?

MapLight Therapeutics, Inc. (MPLT) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 2.02 (Results of Operations and Financial Condition). Updated corporate presentation signals refreshed investor messaging as of November 16, 2026.

What are the latest MPLT SEC filings?

MapLight Therapeutics, Inc. (MPLT) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on October 16, 2026.

What is MPLT's SEC CIK number?

MapLight Therapeutics, Inc. (MPLT)'s SEC Central Index Key (CIK) is 1770069. EDGAR lists every MPLT filing under that number.

Ask anything about MPLT

The research agent reads MPLT's filings, financials, insider trades and 13F holders, then answers with sources.